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Abstract
Background: The objective of this study was to systematically review randomized trials assessing
therapeutic hypothermia as a treatment for term neonates with hypoxic ischemic encephalopathy.
Methods: The Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, CINAHL
databases, reference lists of identified studies, and proceedings of the Pediatric Academic Societies
were searched in July 2006. Randomized trials assessing the effect of therapeutic hypothermia by
either selective head cooling or whole body cooling in term neonates were eligible for inclusion in
the meta-analysis. The primary outcome was death or neurodevelopmental disability at ≥ 18
months.
Results: Five trials involving 552 neonates were included in the analysis. Cooling techniques and
the definition and severity of neurodevelopmental disability differed between studies. Overall,
there is evidence of a significant effect of therapeutic hypothermia on the primary composite
outcome of death or disability (RR: 0.78, 95% CI: 0.66, 0.92, NNT: 8, 95% CI: 5, 20) as well as on
the single outcomes of mortality (RR: 0.75, 95% CI: 0.59, 0.96) and neurodevelopmental disability
at 18 to 22 months (RR: 0.72, 95% CI: 0.53, 0.98). Adverse effects include benign sinus bradycardia
(RR: 7.42, 95% CI: 2.52, 21.87) and thrombocytopenia (RR: 1.47, 95% CI: 1.07, 2.03, NNH: 8)
without deleterious consequences.
Conclusion: In general, therapeutic hypothermia seems to have a beneficial effect on the outcome
of term neonates with moderate to severe hypoxic ischemic encephalopathy. Despite the
methodological differences between trials, wide confidence intervals, and the lack of follow-up data
beyond the second year of life, the consistency of the results is encouraging. Further research is
necessary to minimize the uncertainty regarding efficacy and safety of any specific technique of
cooling for any specific population.
Background
Hypoxic ischemic encephalopathy (HIE) following peri-
natal asphyxia contributes significantly to neonatal mor-
tality and morbidity including long-term
neurodevelopmental sequelae in up to 25%-60% of survi-
vors [1-3]. Despite significant research there is still no
proven intervention for neuroprotection in HIE [4]. The
literature on therapeutic hypothermia as a treatment for
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"white asphyxia" dates as far back as early 60s [5,6]. Exper-
imental studies have shown that mild to moderate hypo-
thermia (33–34°C), applied within the first hours of an
acute hypoxic event, is neuroprotective [7-9]. A Cochrane
review incorporating two small randomized controlled
trials (RCT) has reported no evidence of benefit or harm
related to therapeutic hypothermia in term neonates (N =
50) with HIE [4]. Three large RCTs have been published
since the last substantive amendment of this systematic
review in July 2003 [10-12]. Given the significance of the
condition, and the encouraging results of the recent RCTs,
an up to date systematic review was conducted to evaluate
the efficacy and safety of therapeutic hypothermia in term
neonates with HIE [13,14].
Methods
RCTs comparing therapeutic hypothermia, by either selec-
tive head cooling or whole body cooling, with normoth-
ermia in term neonates with perinatal asphyxia and HIE
were eligible. Asphyxia was considered to be present if at
least one of the following criteria was met: Apgar score of
≤ 5 at 10 minutes, at least one cord pH or arterial pH ≤ 7.1
or base deficit ≥ 12 within the first hour of life, ongoing
resuscitation or mechanical ventilation at 10 minutes of
life. HIE had to be defined by standardized neurological
examination [15,16]. Neonates with major congenital
abnormalities were excluded.
The primary outcome was a composite of death or neu-
rodevelopmental disability at ≥ 18 months of life. Disabil-
ity included cerebral palsy (CP) according to the Gross
Motor Function Classification System (GMF) [17] or
another validated scale, developmental delay as measured
by Griffiths or Bayley assessment [18,19], intellectual
impairment (IQ > 2 SD below the mean), blindness
(vision < 6/60 in both eyes), and hearing loss requiring
amplification. Secondary outcomes included individual
components of the primary composite outcome and
adverse events such as sinus bradycardia, arrhythmia, arte-
rial hypotension (mean arterial pressure < 40 mm Hg),
thrombocytopenia, coagulopathy, anemia, hypoglyc-
emia, abnormal renal function (urine output < 0.5ml/kg/
hour and/or serum creatinine > 0.09 mmol/l), hepatic
dysfunction (aspartate aminotransferase > 200 IU/l,
alanine aminotransferase > 100 IU/l), sepsis, seizures and
hypokalemia.
A systematic literature search was conducted in July 2006
according to the methodology of the Cochrane Neonatal
Review Group. The databases searched included the
Cochrane Database of Systematic Reviews (Issue 3, 2006),
the Cochrane Central Register of Controlled Trials,
EMBASE, CINAHL, and MEDLINE databases using the
following search strategy: "Infant, Newborn" [MeSH]
AND ("Hypothermia" [MeSH] OR "Hypothermia,
Induced" [MeSH]) AND ("Asphyxia" [MeSH] OR
"Asphyxia Neonatorum" [MeSH] OR "Hypoxia-Ischemia,
Brain" [MeSH] OR "hypoxic ischemic encephalopathy"
OR "hypoxic ischemic encephalopathy"). Cross-refer-
ences of publications were checked. A hand search of the
proceedings of the Pediatric Academic Societies published
in Pediatric Research from 1980 was conducted. No lan-
guage restrictions were applied. SKP and SMS designed
the review protocol. All authors searched the literature
independently and assessed inclusion criteria and quality
of the trials. SMS and SR independently extracted the data.
Inconsistencies were sorted out by discussion. Trial qual-
ity was assessed by method of randomization, conceal-
ment of patient allocation, blinding of intervention,
blinding of outcome assessors, and completeness of fol-
low-up.
Meta-analysis was performed using Review Manager soft-
ware (RevMan, version 4.2.7 for Windows, Oxford, Eng-
land: The Cochrane Collaboration, 2003). Relative risk
(RR) and risk difference (RD) were calculated with 95%
confidence intervals (CI). Preplanned subgroup analysis
for selective head cooling and whole body cooling was
carried out. The number needed to treat (NNT) or harm
(NNH) was calculated for significant comparisons. Heter-
ogeneity was estimated by the I2 statistic. A fixed effects
model was used. Reporting follows the QUOROM guide-
lines [20].
Results
187 abstracts were identified. Twelve potentially relevant
reports were retrieved for detailed evaluation. A total of
eight reports [10-12,21-25] of five RCTs involving 552
neonates were eligible for inclusion in the analysis. Two
RCTs involved selective head cooling by a cooling cap
[10,21], the other three involved whole body cooling
[11,12,24]. Tables 1, 2, 3 summarize their characteristics
and quality assessment. No significant heterogeneity was
noted using the I2 statistic. Gunn et al published their
results as 3 different reports using 4 sequential tempera-
ture ranges for cooled infants [21-23]. From these 3
reports, we present the combined data on all neonates
randomized to a rectal temperature of 34.0–35.5°C and
refer to the trial as Gunn et al 1998. Eicher et al reported
the safety [25] and efficacy [12] outcomes of therapeutic
hypothermia in two separate publications. For the pur-
pose of this meta-analysis their study is referred to as
Eicher  et al 2005. The studies Eicher et al 2005 and
Shankaran et al 2002 [24] were included in the review
only for analysis of mortality and adverse events because
the follow-up rate in Eicher et al 2005 was low (68%) and
Shankaran et al 2002 did not report long-term follow up.
The reasons for excluding four trials [26-29] from the
meta-analysis and their characteristics are summarized in
Table 4.BMC Pediatrics 2007, 7:30 http://www.biomedcentral.com/1471-2431/7/30
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Results of the meta-analysis
(1) Death or neurodevelopmental disability at ≥ 18 months (Figure 
1)
Three trials [10,11,21] involving 449 neonates assessed
the primary composite outcome of death or neurodevel-
opmental disability at 18 to 22 months of life. The trials
by Gunn et al 1998 and Gluckman et al 2005 (selective
head cooling by a cooling cap) had primary composite
outcome of death or severe neurodevelopmental disability at
18 months defined as severe CP (equivalent to GMF level
3 to 5 in Gluckman et al 2005), Bayley mental develop-
mental index (MDI) < 70, or bilateral cortical visual
impairment.
The trial of Shankaran et al 2005 (whole body cooling)
had a primary composite outcome as death or moderate or
severe neurodevelopmental disability at 18 to 22 months.
Moderate disability was defined as Bayley MDI of 70 to 84
Table 1: Characteristics of included trials
Included trials Selective head cooling Whole body cooling
Gunn 1998 Gluckman 2005 Shankaran 2002 Shankaran 2005 Eicher 2005
Design RCT RCT
Multicenter
RCT
Multicenter
RCT
Multicenter
RCT
Multicenter
Number of 
participants
26 234 19 208 65
Gestation ≥ 37 wks ≥ 37 wks ≥ 36 wks ≥ 37 wks ≥ 35 wks
Inclusion criteria 
(details see Table 2)
Asphyxia and moderate 
to severe HIE
Asphyxia and moderate 
to severe HIE
Asphyxia and moderate 
to severe HIE
Asphyxia and moderate 
to severe HIE
Asphyxia and HIE
Target temperature 
treatment group (°C)
34.5–35.5 (n = 6)
34.0–35.0 (n = 7)
Not analyzed:
36.0–36.5 (n = 6)
35.5–35.9 (n = 6)
34.0–35.0 34.5 33.5 32.5–33.5
Target temperature 
control group (°C)
36.8–37.2 36.5–37.5 36.5 36.5–37.0 36.5–37.5
Site of temperature 
probe
Rectal Rectal Esophageal Esophageal Rectal
Average age at start 
of cooling (min)
294 330 318 302 120
Duration of cooling 
(h)
4 8 – 7 2 7 27 27 24 8
Cooling device Servo-controlled cooling 
cap
Servo-controlled cooling 
cap
Two servo-controlled 
cooling blankets
Two servo-controlled 
cooling blankets
Ice bags followed by one 
servo-controlled cooling 
blanket
Primary outcome Adverse events Composite of death/
severe disability
Adverse events Composite of death/
moderate or severe 
disability
Adverse events
Latest follow-up 
(months)
18 18 Follow-up not reported 18–22 12
Follow-up tools Bayley II Bayley II
GMF
- Bayley II
GMF
Bayley II
Vineland
Table 2: Inclusion criteria of included trials
Selective head cooling Whole body cooling
Gunn 1998 Gluckman 2005 Shankaran 2002 Shankaran 2005 Eicher 2005
Definition of 
asphyxia
5 min Apgar < 7 or 
pH < 7,1 (first hour)
10 min Apgar < 6 or 
resuscitation or pH < 
7.0 or BD# > 16 mmol 
(first hour)
pH < 7.0 or BD > 16 
or (if no blood gas or 
pH 7.01–7.15 or BD# 
10–15 mmol: acute 
perinatal event and 
seizures or HIE*)
10 min Apgar < 6 or 
resuscitation or pH < 
7.0 or BD# > 16 or (if 
no blood gas or pH 
7.01–7.15 or BD# 10–
15 mmol: acute 
perinatal event and 
seizures or HIE*)
10 min Apgar < 6 or 
resuscitation or pH < 
7.0 or BD# > 13 or 
acute perinatal event
Definition of HIE* Sarnat stage 2–3 Pre-randomisation 
EEG and Sarnat stage 
2–3
Modified Sarnat stage 
2–3
Modified Sarnat stage 
2–3
Sarnat stage 1–3
#BD base deficit * Hypoxic ischemic encephalopathyBMC Pediatrics 2007, 7:30 http://www.biomedcentral.com/1471-2431/7/30
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in addition to one or more of the following: GMF level 2,
hearing impairment with no amplification, or a persistent
seizure disorder. Severe disability was defined as any of
the following: GMF level 3 to 5, Bayley MDI < 70, hearing
impairment requiring hearing aids, or blindness.
There is evidence of a significant effect of therapeutic
hypothermia on the primary composite outcome of death
or disability (RR: 0.78, 95% CI: 0.66, 0.92, NNT: 8, 95%
CI: 5, 20) on pooling the data from these 3 trials. Analysis
of the data from Shankaran et al 2005 showed evidence of
benefit of whole body cooling in reducing death or mod-
erate or severe disability (RR: 0.71, 95% CI: 0.54, 0.93,
NNT: 6, 95% CI: 3, 20). Analysis of data from Gunn et al
1998 and Gluckman et al 2005 (selective head cooling)
did not indicate such an effect on death or severe disabil-
ity considering the 95% CI (RR: 0.83, 95% CI: 0.67, 1.03).
The results for the primary composite outcome did not
change significantly on analysis by a random effects
model.
(2) Mortality (Figure 2)
Overall, analysis of data from five trials [10-12,21,24]
demonstrated a beneficial effect of therapeutic hypother-
mia on mortality (RR: 0.75, 95% CI: 0.59, 0.96, NNT: 11,
95% CI: 6, 100). Subgroup analysis indicated no signifi-
cant reduction of mortality after selective head cooling
(RR: 0.84, 95% CI: 0.59, 1.19). However, whole body
Table 3: Quality assessment of included trials
Included Trial Gunn 1998 Gluckman 2005 Shankaran 2002 Shankaran 2005 Eicher 2005
Adequacy of 
method of 
randomisation
Yes
Computer
generated
Yes
Computer
generated, block
Yes
Computer
generated, block
Yes
Computer
generated, block
Yes
Central
website, block
Concealment of 
allocation
Yes
Sealed opaque
envelopes
Yes
Sealed opaque
envelopes
Yes
Central data- 
coordinating center
Yes
Central data- 
coordinating center
Yes
Central website
Blinding of 
intervention
None
Due to nature of 
intervention
None
Due to nature of 
intervention
None
Due to nature of 
intervention
None
Due to nature of 
intervention
None Due to nature 
of intervention
Blinding of 
outcome assessors
Not robustly Yes No Yes Unknown
Completeness of 
follow-up
Yes (96%) Yes (93%) Follow-up not 
reported#
Yes (98%) No (68%)#
# Data from this trial was only pooled for analysis of mortality and adverse events
Table 4: Trials excluded from the analysis
Study Description of the trial Reason for exclusion
Akisu 2003 [26] Randomized trial of 21 neonates with asphyxia, 10 
assigned to head cooling for 72 h, 11 assigned to 
normothermia. Primary outcomes were 
electroencephalographic changes and 
concentrations of platelet activating factor in 
cerebrospinal fluid during the time of treatment
1. Enrolment based on presence of asphyxia only, 
not HIE*
2. Target temperature in hypothermia group 36.0–
36.5°C
3. Time of start of intervention not standardized
4. No clinical follow-up data available
Zhou 2003 [27] Randomized trial of 50 term neonates with 
asphyxia, 27 assigned to head cooling for 72 h, 23 
assigned to normothermia. Primary outcomes were 
echocardiographic changes at the end of the 
intervention
1. Inclusion based on presence of asphyxia only, not 
HIE*
2. No clinical follow-up data available
Shao 2005 [28] Multicenter randomized trial. 206 term neonates 
with HIE*, 127 allocated to head cooling via cooling 
cap for 72 h, 79 assigned to normothermia. Primary 
outcome was a composite of death or severe 
disability at 18 months
1. Concerns about randomization: Large difference 
in group sizes, method of randomization unknown, 
concealment of allocation unknown
2. Ongoing follow-up, currently 45% of survivors 
assessed at 18 months
Lin 2006 [29] Singlecenter trial. 58 term neonates with HIE*, 30 
assigned to head cooling via cooling cap for 72 h, 28 
controls allocated to normothermia. Primary 
outcomes were changes on head computed 
tomography scans after one week and a behavioral 
assessment at 7–10 days
1. Not randomized, group allocation based on odd 
or even date of admission
2. Mean temperature in control group at begin of 
trial 35.7°C (all neonates outborn, no transport cot 
available), timing of enrolment and rewarming of 
control group unclear
3. No follow-up data available
* Hypoxic ischemic encephalopathyBMC Pediatrics 2007, 7:30 http://www.biomedcentral.com/1471-2431/7/30
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cooling did have a protective effect (RR: 0.68, 95% CI:
0.48, 0.97, NNT: 8, 95% CI: 5, 100).
(3) Neurodevelopmental disability at ≥ 18 months (Figure 3)
Analysis of data from three trials [10,11,21] showed a sig-
nificant effect of therapeutic hypothermia on neurodevel-
opmental disability at 18 to 22 months (RR: 0.72, 95% CI:
0.53, 0.98, NNT: 9, 95% CI: 5, 100). Subgroup analysis of
trials of neither selective head cooling assessing severe dis-
ability (RR: 0.76, 95% CI: 0.50, 1.15) nor whole body
cooling assessing moderate or severe disability (RR: 0.67,
95% CI: 0.42, 1.08) showed a significant benefit.
(4) Disabling CP (GMF level 3 to 5) at ≥ 18 months
Pooled data from three trials [10,11,21] didn't show a sig-
nificant effect of therapeutic hypothermia on disabling CP
at 18 to 22 months (RR: 0.69, 95% CI: 0.46, 1.03). Sub-
group analysis of selective head cooling (RR: 0.72, 95%
CI: 0.41, 1.26) or whole body cooling (RR: 0.66, 95% CI:
0.36, 1.18) also did not indicate a significant effect.
(5) Developmental delay (Bayley MDI < 70) at ≥ 18 months
Analysis of data from three trials [10,11,21] didn't dem-
onstrate a significant effect of therapeutic hypothermia on
developmental delay at 18 to 22 months (RR: 0.76, 95%
CI: 0.54, 1.06). Subgroup analysis of selective head cool-
ing (RR: 0.86, 95% CI: 0.54, 1.37) or whole body cooling
(RR: 0.65, 95% CI: 0.40, 1.08) also did not indicate a sig-
nificant benefit.
(6) Blindness at ≥ 18 months
Pooled data from three trials [10,11,21] didn't indicate a
significant effect of therapeutic hypothermia on blindness
assessed at 18 to 22 months (RR: 0.52, 95% CI: 0.27,
1.02). Subgroup analysis of selective head cooling (RR:
0.57, 95% CI: 0.23, 1.37) or whole body cooling (RR:
0.47, 95% CI: 0.16, 1.32) also did not indicate a signifi-
cant benefit.
(7) Hearing loss requiring amplification assessed at ≥ 18 months
Analysis of data from three trials [10,11,21] didn't indi-
cate a significant effect of therapeutic hypothermia on
severe hearing loss at 18 to 22 months (RR: 0.97, 95% CI:
0.36, 2.59). Subgroup analysis of selective head cooling
Primary outcome: death or neurodevelopmental disability at 18 to 22 months. Figure 1
Primary outcome: death or neurodevelopmental disability at 18 to 22 months. Forest plot displays relative risk of 
death or neurodevelopmental disability at 18 to 22 months for all included studies and separately for selective head cooling and 
whole body cooling studies. There is a significant benefit of therapeutic hypothermia on the composite outcome of death or 
disability (RR: 0.78, 95% CI: 0.66, 0.92, NNT: 8, 95% CI: 5, 20). The squares represent the point estimate of treatment effect of 
each study with a horizontal line extending on either side of the square representing the 95% confidence interval. The dia-
monds represent the overall and subgroup relative risk estimate of the studies presented in the meta-analysis. The widths of 
the diamonds represent the 95% confidence interval of the relative risk. The vertical midline of the forest plot corresponding 
to a relative risk of 1 represents a "no effect" line. Gunn et al 1998 and Gluckman et al 2005 assessed death or severe disability, 
Shankaran et al 2005 reported on death or moderate or severe disability as described in the results.BMC Pediatrics 2007, 7:30 http://www.biomedcentral.com/1471-2431/7/30
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(RR: 1.43, 95% CI: 0.36, 5.72) or whole body cooling (RR:
0.62, 95% CI: 0.14, 2.68) also did not indicate a signifi-
cant effect.
(8) Adverse events
Sinus bradycardia [12,15,17,30] (RR: 7.42, 95% CI: 2.52,
21.87, NNH: 13, 95% CI: 8, 20) and thrombocytopenia
[12,15,17] (RR: 1.47, 95% CI: 1.07, 2.03, NNH: 8, 95%
CI: 5, 50) were reported as significant adverse events
(Thrombocytopenia: Gunn et al 1998 and Eicher et al
2005: platelet count < 150000/µl, Gluckman et al 2005: <
100000/µl). Only Gluckman et al 2005 reported higher
mean plasma glucose concentrations between 4 h and 24
h in cooled vs control infants which resolved spontane-
ously [10]. There were no other significant adverse effects
(Table 5).
Discussion
Our results suggest that in general, cooling of neonates
with HIE has a beneficial effect on the primary composite
outcome of death or disability at 18–22 months. The sim-
ilarity of outcomes between trials despite the heterogene-
ity related to various factors including methodology of
cooling (head vs. body, devices, target temperatures, site
of monitoring, duration of intervention etc.), patient
characteristics (place of birth, temperature and age at
enrolment etc.), and the definition and degree (moderate
and/or severe) of neuro-developmental disability (Table
1) is reassuring for the generalisability of the findings. Dif-
ferences in the behavior of the composite outcome vs. its
individual components are an important consideration
[30]. The selection of death and neurodevelopmental dis-
ability as components of the prespecified primary com-
posite outcome is justified. The frequency of the
components of the primary composite outcome is signifi-
cant and comparable, assuring that no individual compo-
nent is driving it in any specific direction. The data show
reasonably convincingly that the benefit for the primary
composite outcome is significant and is probably a fair
reflection of benefit for its individual components. Indi-
vidual components of the primary composite outcome
show significant benefits of cooling but have wide CIs
suggesting that more data is needed to minimize the
uncertainty. However, it is important to note that inter-
pretation of CI is a personal and subjective issue. Overall,
there seems to be reasonably good evidence of a real ben-
efit of cooling on the primary composite outcome and its
components.
Secondary outcome: mortality. Figure 2
Secondary outcome: mortality. Forest plot displays relative risk of death for all included studies and separately for selec-
tive head cooling and whole body cooling studies. There is a significant benefit of therapeutic hypothermia on the single out-
come of mortality (RR: 0.75, 95% CI: 0.59, 0.96, NNT: 11, 95% CI: 6, 100). The squares represent the point estimate of 
treatment effect of each study with a horizontal line extending on either side of the square representing the 95% confidence 
interval. The diamonds represent the overall and subgroup relative risk estimate of the studies presented in the meta-analysis. 
The widths of the diamonds represent the 95% confidence interval of the relative risk. The vertical midline of the forest plot 
corresponding to a relative risk of 1 represents a "no effect" line.BMC Pediatrics 2007, 7:30 http://www.biomedcentral.com/1471-2431/7/30
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The definition of disability in the whole body cooling trial
by Shankaran et al is quite different from that in the selec-
tive head cooling trials by Gluckman et al and Gunn et al
(moderate/severe vs. only severe disability). However the
effect of this difference in definitions on the results of the
meta-analysis is limited because the proportion of infants
with moderate disability is low in all trials. Subgroup
analysis seems to suggest that the results of the selective
head cooling trials are not as convincing as those of the
whole body cooling trials. However, there might be no
clinically important difference between these cooling
techniques for several reasons: Firstly, this subgroup anal-
ysis is clearly dominated by the two major trials Gluck-
man et al and Shankaran et al, and therefore of limited
value. The overall trend for both cooling techniques is
towards a benefit (Figure 1). Secondly, differences in the
severity of neuronal injury may explain these findings
considering the differences in the inclusion criteria of
those two trials (Table 2). The proportion of neonates
with very low Apgar scores, severe aEEG background activ-
ity and severe clinical encephalopathy was higher in the
intervention group in Gluckman et al, possibly reducing
the chances to demonstrate selective head cooling bene-
fits. A significant reduction in death or major disability
was however noted in the prespecified subgroup analysis
of neonates with only moderate injury defined by aEEG
criteria [10,31]. Thirdly, palliation bias in the form of a
higher rate of withdrawal of treatment (27 vs. 12) in the
control group may also have played a role in the signifi-
cant benefit reported in the whole body cooling trial by
Shankaran et al [32]. In addition, 41/106 neonates in the
control group of Shankaran et al, at least once had a tem-
perature > 38°C within the 72 hours of the intervention,
which may have influenced for their outcome [32].
The frequency of sinus bradycardia following therapeutic
hypothermia was significant. A borderline effect on
thrombocytopenia was noted and there was a trend
towards a higher risk of anemia, coagulopathy, and hypo-
tension (Table 5). However, sinus bradycardia is a physi-
ological response rather than a true adverse event and did
not compromise perfusion, and thrombocytopenia was
not reported as of clinical importance. The adverse events
therefore may be outweighed by the potential benefits.
Secondary outcome: neurodevelopmental disability at 18 to 22 months. Figure 3
Secondary outcome: neurodevelopmental disability at 18 to 22 months. Forest plot displays relative risk of neurode-
velopmental disability at 18 to 22 months for all included studies and separately for selective head cooling and whole body 
cooling studies. There is a significant benefit of therapeutic hypothermia on the single outcome of neurodevelopmental disabil-
ity at 18 to 22 months (RR: 0.72, 95% CI: 0.53, 0.98, NNT: 9, 95% CI: 5, 100). The squares represent the point estimate of 
treatment effect of each study with a horizontal line extending on either side of the square representing the 95% confidence 
interval. The arrowheads indicate a wide confidence interval that is compressed to fit the scale. The diamonds represent the 
overall and subgroup relative risk estimate of the studies presented in the meta-analysis. The widths of the diamonds represent 
the 95% confidence interval of the relative risk. The vertical midline of the forest plot corresponding to a relative risk of 1 rep-
resents a "no effect" line. Gunn et al 1998 and Gluckman et al 2005 assessed severe disability, Shankaran et al 2005 reported on 
moderate or severe disability as explained in the results.BMC Pediatrics 2007, 7:30 http://www.biomedcentral.com/1471-2431/7/30
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Given the overall encouraging results without significant
adverse effects it is not surprising that some centers may
now consider therapeutic hypothermia as a standard treat-
ment for HIE [33]. However, many experts including a
commission of the American Academy of Pediatrics [34]
have suggested that further research should continue and
therapeutic hypothermia should not be offered outside
RCTs. Their suggestions are based on heterogeneity as dis-
cussed above and the possibility that neurological out-
comes at 18 to 22 months may not reflect the true long-
term benefits [35,36]. The rate of severe disability is very
unlikely to change, however, more subtle neurodevelop-
mental problems that cannot be assessed at the age of 18
months may become apparent by school age [1]. The
unaddressed issues include the specific target population
that is most likely to benefit, the most effective and safe
method for cooling, the optimal age at onset and duration
of cooling, and the field difficulties in applying any spe-
cific method for cooling, particularly for outborn
neonates [34]. In practice, hypothermia is quite frequent
in asphyxiated neonates, whereas guidelines for rewarm-
ing are not standardised/uniform. The targets, methods as
well as the speed of rewarming may influence the neuro-
nal recovery/damage following HIE. This issue is espe-
cially important during transport of hypothermic
neonates with HIE. The field difficulties have been
addressed to some extent by Eicher et al who showed that
it is feasible to cool outborn neonates with ice bags fol-
lowed by cooling with a blanket on reaching the receiving
hospital. This approach can help to reduce the time
between birth asphyxia and initiation of cooling. Animal
studies have clearly shown that there is a correlation
between early onset of cooling and treatment effect [37].
Experts have advised that centers wishing to offer thera-
peutic hypothermia outside RCTs should adhere strictly to
a trial protocol and have established the substantial
resources required to cool neonates with HIE. The mini-
mum resources include a transport team to retrieve
neonates and start cooling before four to six hours of life
and a multidisciplinary team for long-term neurodevelop-
mental follow-up [33].
At least three more RCTs of therapeutic hypothermia aim-
ing at a combined total of over 650 neonates are currently
in progress [38-40]. The long-term outcomes ≥ 18 months
of age of the single trial with complete recruitment
(according to the TOBY trial website) will not be ready for
publication until end of 2008 at the earliest [38]. Ideally
it is preferable to include the long-term results of those
ongoing studies in this systematic review to have defini-
tive answers. However, those studies are not designed to
answer all the unaddressed issues listed earlier, therefore
waiting for their results is ethically complex. They may
show beneficial effects of therapeutic hypothermia while
narrowing the CI. In that case it is disturbing to think that
while waiting for the CI to narrow the purists may have
denied a beneficial intervention to neonates with HIE.
Obviously ethics [41], resources, parents' wishes, and last
but not the least, the anxiety related to future medicolegal
challenges, will have to be balanced before deciding
whether therapeutic hypothermia can be offered as a
standard treatment for HIE. Continuing to participate in a
trial of therapeutic hypothermia while offering it to
neonates whose parents insist on it probably violates the
principle of equipoise, the very justification for conduct-
ing a RCT.
Conclusion
Evidence from high quality RCTs indicates that overall,
cooling of neonates with moderate to severe HIE reduces
the risk of death or disability at 18 to 22 months without
Table 5: Analysis of adverse effects of therapeutic hypothermia
Number of included trials Number of 
participants
Adverse event Relative risk (95% CI)
4 [10,11,21,25] 526 Sinus bradycardia 7.42 (2.52, 21.87)
Number needed to harm: 13 (95% CI: 8, 20)
3 [10,11,21] 464 Arrhythmia requiring treatment 1.04 (0.07, 16.39)
4 [10,11,21,24] 483 Hypotension 1.17 (0.96, 1.42)
3 [10,21,25] 318 Thrombocytopenia 1.47 (1.07, 2.03)
Number needed to harm: 8 (95% CI: 5, 50)
3 [10,11,25] 500 Coagulopathy 1.28 (0.94, 1.75)
2 [10,25] 292 Anemia 1.75 (0.86, 3.57)
3 [10,11,21] 464 Hypoglycemia 0.76 (0.49 to 1.17)
5 [10,11,21,24,25] 545 Abnormal renal function 0.91 (0.79 to 1.05)
2 [10,11] 448 Hepatic dysfunction 0.83 (0.64, 1.09)
4 [10,11,21,25] 526 Sepsis 1.04 (0.45 to 2.39)
5 [10,11,21,24,25] 545 Seizures 1.04 (0.91 to 1.18)
2 [10,25] 292 Hypokalemia 1.02 (0.84 to 1.25)BMC Pediatrics 2007, 7:30 http://www.biomedcentral.com/1471-2431/7/30
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significant adverse effects. Despite the methodological
differences, wide CIs, and lack of long-term follow-up
data, the consistency of benefits and its sound scientific
basis indicate that cooling may be an attractive option for
neuroprotection in HIE – a condition that lacks any effec-
tive treatment at present.
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